MedTrace Logo

A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255

NCT03174613 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-09-18

No results posted yet for this study

Summary

1. To evaluate the safety and tolerability of LC51-0255 in healthy male subjects
2. To evaluate the pharmacokinetic/pharmacodynamics characteristics (PK/PD) of LC51-0255 in healthy male subjects
3. To evaluate bioavailability of LC51-0255

Conditions

  • Healthy

Interventions

DRUG

LC51-0255

0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg

DRUG

Placebo

0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu, MD,M.B.A. · Seoul National University Hospital, Clinical Trial Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2019-06-12
Completion
2019-07-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03174613 on ClinicalTrials.gov